NHS Lothian and Nucleix Presented Data at EAU25 Showcasing Potential of Bladder EpiCheck® to Improve Detection of Disease Recurrence in Non-Muscle Invasive Bladder Cancer (NMIBC) Patients

EDINBURGH, Scotland & SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–NHS Lothian, Scotland’s second largest health authority providing a comprehensive range of primary, community-based and acute hospital services, and Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from an abstract featuring Nucleix’s Bladder EpiCheck® test presented at the 46th Annual European Association of Urology (EAU) Congress.

Subscribe to one of our social media channels